

Application No.: 09/823,418

2

Docket No.: 220002059711

**AMENDMENTS TO THE CLAIMS**

Please enter the following amendments without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the claims****Claims 1-22 (Canceled)**

**Claim 23 (Currently Amended):** An isolated and purified polynucleotide encoding an apo-B100 protein comprising a proteoglycan receptor<sup>+</sup> mutation in Site B, wherein Site B is equivalent to amino acids from about 3358 to about 3369 of the human apo-B100 protein and wherein the mutation comprises at least one amino acid substitution or deletion of at least one of Lys<sub>3363</sub>[[,]] or Arg<sub>3362</sub>[[,] or Arg<sub>3364</sub>].

**Claims 24-28 (Canceled)**

**Claim 29 (Previously presented):** The polynucleotide encoding an apo-B100 protein according to claim 23, wherein said at least one amino acid substitution in site B is an amino acid a residue selected from the group consisting of Gly, Ala, Val, Leu, Ile, Phe, Tyr, Trp, Cys, Met, Asn, Gln, Asp, and Glu.

**Claim 30 (Previously presented):** The polynucleotide encoding an apo-B100 protein according to claim 23, wherein said mutation in Site B comprises replacement of all of the arginine residues and lysine residues with neutral amino acid residues.

**Claim 31 (Previously presented):** The polynucleotide encoding an apo-B100 protein according to claim 30, wherein said arginine residues are replaced with serine residues and said lysine residues are replaced with alanine residues.

sd-229588

Application No.: 09/823,418

3

Docket No.: 220002059711

**Claim 32** (Currently Amended): The polynucleotide encoding an apo-B100 protein according to claim 23, wherein said amino acid sequence from position 3358 to 3367 is SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:13, or SEQ ID NO:14, or SEQ ID NO:15.

**Claim 33** (Previously presented): The polynucleotide encoding an apo-B100 protein according to claim 23, wherein said mutation in Site B is at position 3363 and the lysine residue is replaced with a glutamic acid residue, and the amino acid sequence from position 3358 to 3367 is:

Thr<sub>3358</sub>-Arg<sub>3359</sub>-Leu<sub>3360</sub>-Thr<sub>3361</sub>-Arg<sub>3362</sub>-Glu<sub>3363</sub>-Arg<sub>3364</sub>-Gly<sub>3365</sub>-Leu<sub>3366</sub>-Lys<sub>3367</sub> (SEQ ID NO:1).

**Claim 34** (Previously presented): An isolated and purified polynucleotide encoding an apo-B100 protein comprising a proteoglycan receptor<sup>+</sup> mutation in Site B, wherein Site B is equivalent to amino acids from about 3358 to about 3369 of the human apo-B100 protein and wherein the mutation comprises at least one amino acid addition to site B.

**Claim 35** (Previously presented): The polynucleotide encoding an apo-B100 protein according to claim 34, wherein said mutation in Site B is an addition of a single amino acid between positions 3362 and 3364.

**Claim 36** (Previously presented): The polynucleotide encoding an apo-B100 protein according to claim 34, wherein said at least one amino acid addition to site B is selected from the group consisting of Gly, Ala, Val, Leu, Ile, Phe, Tyr, Trp, Cys, Met, Asn, Gln, Asp, and Glu.

**Claim 37** (Previously presented): The polynucleotide encoding an apo-B100 protein according to claim 34, wherein said amino acid sequence from position 3358 to 3367 is SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 or SEQ ID NO:19.

**Claim 38** (Previously presented): An isolated and purified polynucleotide encoding an apo-B100 protein comprising a proteoglycan receptor<sup>+</sup> mutation in Site B, wherein Site B is equivalent to amino acids from about 3358 to about 3369 of the human apo-B100 protein and wherein the

sd-229588

Application No.: 09/823,418

4

Docket No.: 220002059711

mutation comprises a deletion of amino acid Arg<sub>3359</sub> or a substitution of amino acid Arg<sub>3359</sub> by an amino acid selected from the group consisting of Gly, Ala, Val, Leu, Ile, Phe, Tyr, Trp, Cys, Met, Asn, Gln, Asp, and Glu.

**Claim 39** (Previously presented): The polynucleotide encoding an apo-B100 protein according to claim 38, wherein said amino acid sequence from position 3358 to 3367 is SEQ ID NO:11 or SEQ ID NO:12.

**Claim 40** (New): An isolated and purified polynucleotide encoding an apo-B100 protein comprising a proteoglycan receptor<sup>+</sup> mutation in Site B, wherein Site B is equivalent to amino acids from about 3358 to about 3369 of the human apo-B100 protein and wherein the mutation comprises at least one amino acid substitution or deletion of Arg3364, wherein said at least one amino acid substitution in site B is an amino acid a residue selected from the group consisting of Gly, Ala, Val, Leu, Ile, Phe, Tyr, Trp, Cys, Met, Asn, Gln, Asp, and Glu.

**Claim 41** (New): The polynucleotide encoding an apo-B100 protein according to claim 40, wherein said amino acid sequence from position 3358 to 3367 is SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:15.

sd-229588